

This is the peer reviewed version of the following article:

Rituximab retention rate in systemic sclerosis: a long term real-life multicenter study / De Luca, Giacomo; De Lorenzis, Enrico; Campochiaro, Corrado; Cacciapaglia, Fabio; Del Papa, Nicoletta; Zanatta, Elisabetta; Airò, Paolo; Grazia Lazzaroni, Maria; Giuggioli, Dilia; De Santis, Maria; Alonzi, Gabriella; Stano, Stefano; Binda, Marco; Moccaldi, Beatrice; Tonutti, Antonio; Cavalli, Silvia; Batani, Veronica; Natalello, Gerlando; Iannone, Florenzo; Antonietta D'Agostino, Maria; Dagna, Lorenzo; Matucci-Cerinic, Marco; Laura Bosello, Silvia. - In: RHEUMATOLOGY. - ISSN 1462-0324. - keae280(2024), pp. 0002-0023. [10.1093/rheumatology/keae280]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

01/09/2024 14:28

(Article begins on next page)

01/09/2024 14:28

**Rituximab retention rate in systemic sclerosis: a long term real-life multicenter study.**

Giacomo De Luca<sup>1,2</sup>, Enrico De Lorenzis<sup>3</sup>, Corrado Campochiaro<sup>1,2</sup>, Fabio Cacciapaglia<sup>4</sup>, Nicoletta Del Papa<sup>5</sup>, Elisabetta Zanatta<sup>6</sup>, Paolo Airò<sup>7</sup>, Maria Grazia Lazzaroni<sup>7</sup>, Dilia Giuggioli<sup>8</sup>, Maria De Santis<sup>9,10</sup>, Gabriella Alonzi<sup>3</sup>, Stefano Stano<sup>4</sup>, Marco Binda<sup>6</sup>, Beatrice Moccaldi<sup>6</sup>, Antonio Tonutti<sup>9,10</sup>, Silvia Cavalli<sup>5</sup>, Veronica Batani<sup>1,2</sup>, Gerlando Natalello<sup>3</sup>, Florenzo Iannone<sup>4</sup>, Maria Antonietta D'Agostino<sup>3</sup>, Lorenzo Dagna<sup>1,2</sup>, Marco Matucci-Cerinic<sup>1,2</sup>, Silvia Laura Bosello<sup>3</sup>.

<sup>1</sup>*Scleroderma Unit, Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Italy*

<sup>2</sup>*Vita-Salute San Raffaele University, Milan, Italy*

<sup>3</sup>*Rheumatology Unit, Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.*

<sup>4</sup>*Rheumatology Unit - DiMePre-J University of Bari, Bari, Italy.*

<sup>5</sup>*Scleroderma Clinic, ASST Gaetano Pini-CTO, Milan, Italy*

<sup>6</sup>*Rheumatology Unit, Padova University Hospital, Padova, Italy*

<sup>7</sup>*Scleroderma Unit, UOC Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy*

<sup>8</sup>*Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena*

<sup>9</sup>*Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Italy*

<sup>10</sup>*Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy*

**Corresponding author:**

Giacomo De Luca, MD

Scleroderma Unit

Unit of Immunology, Rheumatology, Allergy and Rare Diseases

Vita-Salute San Raffaele University

IRCCS San Raffaele Hospital

Via Olgettina 60, 20132 Milano (MI), Italy

Phone: +390226437060 Fax: +390226433729

E-mail: [deluca.giacomo@hsr.it](mailto:deluca.giacomo@hsr.it)

ORCID ID: 0000-0002-5306-7714

## ABSTRACT

**Objectives:** to report real-life data on rituximab retention-rate as indicator of safety and efficacy in a multicentric national cohort of systemic sclerosis patients.

**Methods:** SSc patients treated with rituximab and followed for at least 36 months were included, clinically characterized, and longitudinally monitored. A competing risk analysis with sub-Hazard Ratio(sHR) definition was performed to explore the clinical variables linked to specific cause of rituximab discontinuation.

**Results:** One-hundred-fifty-two SSc-patients (mean age  $47.3 \pm 12.3$  years; females 79.6%; diffuse disease 77.6%; anti-topoisomerase-I positivity 63.2%) were evaluated over a median(IQR) time of 3.3(1.7-5.0) years. The primary indication for rituximab were interstitial lung disease (ILD)(38.8%), worsening skin fibrosis(36.8%), and arthritis(13.8%); 138 patients(90.8%) received more than one rituximab course. The 5-years rituximab retention rate was 59.9%(44.6-64.7%). Clinical response was the most common reason for rituximab discontinuation[5.7(3.7-8.4) per 100 patient-year] and was associated with a shorter disease duration[sHR 0.8(0.7-0.9)], anti-topoisomerase-I negativity[sHR 0.4(0.2-0.9)], previous digital ulcers[sHR 2.6(1.1-6.2)] and no history of arthritis[sHR 0.3 (0.1-0.8)]. Treatment failure was the second cause of rituximab discontinuation[3.7(2.2-6.0) per 100 patient-year] and was associated with anti-centromere antibody positivity[sHR 2.8(1.1-7.4)] and anti-topoisomerase-I negativity[sHR 0.2(0.1-0.6)]. Adverse events(AEs) were the less common cause of discontinuation[3.1(1.7-5.2) per 100 patient-year], associated with limited cutaneous subset[sHR 3.4(1.2-9.7)] and previous mycophenolate mofetil treatment[sHR 4.5(1.2-16.3)].

**Conclusion:** rituximab is a safe and effective treatment in SSc: clinical response emerged as the primary reason for rituximab discontinuation, and AEs had a limited impact on treatment persistence. The identification of specific disease features associated with a response to rituximab will be useful in the management of SSc-patients.

1  
2  
3 **Keywords:** systemic sclerosis, rituximab, retention rate, real-life data, B-cells.  
4  
5  
6  
7

8 **Key messages**  
9

- 10 • Rituximab is safe in systemic sclerosis: adverse events have a limited impact on treatment  
11 persistence.  
12
- 13 • Rituximab is effective in systemic sclerosis, clinical response being the primary reason for  
14 discontinuation.  
15
- 16 • The identification of specific disease features associated with a response to rituximab is  
17 eagerly awaited.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Systemic sclerosis (SSc) is a severe immune-mediated disease characterized by diffuse vascular damage and aberrant activation of the immune system, resulting in inflammation and fibrosis of skin and internal organs [1-2]. Immunosuppressive strategies to treat SSc are not yet established as only a limited number of treatments have shown efficacy and safety [3-7]. Consequently, the disease-related mortality rate remains high, primarily due to lung and heart involvement [8].

In SSc patients with progressive skin and lung involvement, experimental and clinical data support the therapeutic use of the monoclonal antibody rituximab (RTX), which targets human CD20 [4,5,7,9-11]. A recent large prospective non-randomized EUSTAR study confirmed the effectiveness and safety of RTX, showing significant improvement in skin fibrosis and a stabilization of lung function [9].

Recently, in the DESIRES study (a double-blind, investigator-initiated, randomized, placebo-controlled phase 2 clinical trial) RTX led to significant reduction of skin involvement extension, evaluated by the modified Rodnan skin score (mRSS) [7] compared to placebo at 24-weeks. Furthermore, the study indicated that in patients with SSc-related interstitial lung disease (ILD), the change in the percentage of predicted forced vital capacity (FVC) favored RTX-treated group over placebo. Subsequently, these findings were validated in a 24-week open-label extension phase of the DESIRES trial [12]. The usefulness of RTX to treat SSc-related ILD also emerged in the recent RECITAL study, a double-blind, double-dummy, randomized, controlled, phase 2b trial showing that rituximab is not superior to cyclophosphamide to treat patients with ILD associated with connective tissue diseases, including SSc [13]. Participants in both groups, indeed, had increased FVC at 24 months and improved quality of life. Nevertheless, the long-term efficacy and safety of RTX therapy in SSc have not been fully confirmed in prospective clinical trials. Likewise, real-life data on the long-term safety and efficacy of RTX are limited.

The aim of this study was to evaluate the real-life RTX retention rate as an indicator of safety and efficacy in a multicentric cohort of Italian SSc patients.

## METHODS

### Study design, sample and data collection

An observational retrospective longitudinal study was designed to analyze data from SSc patients followed-up in eight Italian Scleroderma referral centers.

The patients included in the analysis, classified as SSc according to SSc 2013 ACR/EULAR classification criteria [14], were treated with at least one complete RTX course between October 2006 and February 2020, and had a follow-up of at least 36 months. The study included patients treated with RTX originator (RTX-O) or RTX biosimilars (RTX-B), as well as those who switched to RTX-B receiving at least one course of RTX-O.

Clinical data were extracted retrospectively through a medical chart review process. Electronic health records were evaluated based on a standard workflow agreed in preliminary meetings among all authors. The data extraction was carried out by clinicians involved in the management of SSc patients. Clinical indications for B-cell depleting therapy were recorded based on organ involvement and the clinical manifestations, with a primary clinical reason for RTX initiation clearly identified for each patient. Data on RTX therapeutic regimen at the first therapeutic course and during follow-up were also collected.

For all patients, a comprehensive analysis of disease characteristics and organ involvement was available. The collected disease characteristics included: disease subset, i.e. limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc) disease, autoantibody profile, disease duration (calculated from the first non-Raynaud's symptom), extent of skin involvement according to mRSS, and presence of SSc-related organ involvements (including lung, i.e. ILD diagnosed at lung high resolution computed tomography [HRCT] and/or pulmonary arterial hypertension [PAH] at right heart catheterization, primary heart involvement [15], arthritis, myositis, history of digital ulcers [DUs] or presence of active DUs at time of enrollment, gastro-intestinal involvement and renal crisis).

1  
2  
3 Patients were longitudinally monitored for up to 5 years, starting from the index date of RTX  
4 introduction. The follow-up period ended at treatment discontinuation, death from any cause, or the  
5 conclusion of the available follow-up, whichever occurred first.  
6  
7

8  
9  
10 The following outcome measures were evaluated: (i) RTX discontinuation for any reason, (ii) RTX  
11 discontinuation due to adverse events (AEs), (iii) RTX discontinuation due to treatment failure, (iv)  
12 RTX discontinuation due to AEs and treatment failure, (v) RTX discontinuation due to clinical  
13 efficacy.  
14  
15  
16  
17

18  
19 Clinical response was defined as: i) improvement of at least 5 points or of the 25% in patients with  
20 baseline mRSS >25 [16] in patients with diffuse progressive skin disease, i.e. the minimal clinically  
21 important differences (MCIDs) for the mRSS in dSSc patients [17-19]; ii) absence of lung function  
22 deterioration defined according to OMERACT criteria as a relative FVC reduction of 10% or a  
23 simultaneous FVC relative reduction of 5% and a relative alveolar diffusion of carbon monoxide  
24 (DLCO) relative reduction of 15% [20]; iii) clinical remission of arthritis, measured with disease  
25 activity score on 28 joints (C-reactive protein [CRP]-DAS28) (DAS28<2.6) [21]; iv) resolution or  
26 improvement of other specific disease features, if present and considered as the main clinical  
27 indication for RTX therapy, as: active and recurrent DUs, myositis (based on clinical signs and total  
28 creatine phosphokinase serum levels), and myocarditis (based on clinical signs, high-sensitive  
29 troponin T and/or cardiac magnetic resonance findings).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Any change in immunosuppressive therapy during follow-up, including the addition or switch of  
45 conventional or biologic disease modifying anti-rheumatic drugs (DMARDs), and addition of the  
46 anti-fibrotic drug nintedanib for progressive ILD, was recorded. The following outcome measures  
47 after rituximab discontinuation at the latest available follow-up were also recorded: disease-related  
48 deaths, any change in immunosuppressive therapy, the addition of anti-fibrotic therapy, and need for  
49 autologous haematopoietic stem cell transplantation (AHSTC) or lung transplantation.  
50  
51  
52  
53  
54  
55  
56  
57

58 Data on repeated RTX courses during follow-up were collected. According to clinical practice at each  
59 referral center, mRSS was evaluated at baseline and at least every 6 months after the first RTX course  
60



1  
2  
3 during follow-up. Pulmonary function tests (PFTs) with FVC, total lung capacity (TLC), and DLCO  
4 before RTX treatment and during follow-up were also reviewed.  
5  
6

7 All AEs that occurred after RTX initiation were recorded, including hospitalization and severe AEs.  
8  
9

10 The study was conducted in accordance with the recommendations of the Declaration of Helsinki and  
11 was specifically approved by the local ethical committee at coordinating center (*Comitato Etico*  
12 *IRCCS Ospedale San Raffaele – study code: IMMUNORADAR*). The local ethical committees of all  
13 centers approved the study (*Supplemental file; supplementary table 3*). A written informed consent  
14 was obtained from each patient at each center according to local procedures.  
15  
16  
17  
18  
19  
20  
21  
22

### 23 **Statistical analysis**

24 Categorical variables were presented as numbers and percentages. Continuous variables were  
25 presented either as mean with standard deviation (SD) or as median with interquartile range (IQR),  
26 depending on the normality of the distribution as indicated by quantile-quantile plots.  
27  
28  
29

30 The occurrence of outcomes was quantified in terms of incidence rate and 5-year cumulative  
31 incidence, with a 95% confidence interval (CI). The Kaplan-Meier method was used to compute the  
32 cumulative incidence in the at-risk population. A competing risk analysis was conducted to explore  
33 the clinical variables associated with RTX discontinuation for each specific cause, in comparison to  
34 alternative causes. The outcome sub-distribution hazard function was modeled using the Fine-Gray  
35 regression model. Associations were expressed as a sub-Hazard Ratio (sHR) with a 95% CI. For the  
36 multivariate analysis, a p-value of less than 0.05 was considered statistically significant, and all tests  
37 were two-tailed. The statistical analysis was performed using RStudio, version 2023.06.1  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

## 53 **RESULTS**

### 54 *Baseline evaluation and reasons for RTX initiation*

55 We enrolled 152 SSc patients from 8 centres. The cohort had a mean age of  $47.3 \pm 12.3$  years, with  
56 79.6% females and a mean disease duration of  $146.9 \pm 79.2$  months. The majority of patients  
57  
58  
59  
60

presented with a dSSc (77.7%) with ILD in 75.7% of cases, gastrointestinal involvement in two-third of cases, and history of DUs in 59.9%. Overall, musculoskeletal involvement was diagnosed in the 41.4% of patients, while primary heart involvement, PAH and renal disease were only rarely present.

The demographic and clinical characteristics of SSc patients are summarized in Table 1.

Notably, almost all patients (92.8%) received previous immunosuppressive therapy, primarily mycophenolate mofetil (MMF) (44.7%) or cyclophosphamide (29.6%). At the time of RTX initiation, a substantial proportion of patients (70.4%) were concomitantly receiving DMARDs, predominantly MMF (37.5%) or methotrexate (36.2%). Previous and concomitant therapies are provided in Table 2.

### ***RTX regimens and follow-up***

The main reason for initiating RTX was ILD progression in 38.8% of patients, worsening skin fibrosis in 36.8%, and presence of arthritis in 13.8%. RTX was prescribed for multiple indications in 41 cases (27.0%), with 21 patients (13.8%) receiving RTX for concomitant skin and lung disease progression.

The majority of patients (n.71) received RTX-O (46.7%) and later switched to RTX-B. In contrast, 61 patients (40.1%) received RTX-B from the first therapeutic course, and only 20 patients (13.2%) remained on RTX-O. Almost all patients (98.7%) were treated with a dose of RTX 1000 mg repeated after 15 days, while only 2 patients received RTX 500 mg every 7 days for 4 weeks.

Patients were monitored for up to 5 years, with the median (IQR) follow-up time being 3.3 (1.7-5.0) years.

During this period, 138 patients (90.8%) underwent more than one RTX course (median of 4 [3-8] courses). In 113 cases (81.9%), RTX was repeated at 6 months while in 25 cases (18.1%) the timing of subsequent courses was clinically driven, i.e. administered on demand.

Most patients who received at least a second course of RTX after 6 months continued with the same therapeutic regimen (62.5%). However, the RTX dose was reduced to a single 1000 mg dose in 34 cases (22.4%) and to a single 500 mg dose in 6 cases (3.5%), due to the satisfactory clinical response.

Changes in concomitant therapies after the first RTX course and during the follow-up period are detailed in Supplemental Table 1.

### ***RTX retention rate and causes of discontinuation***

The retention rate of RTX over five years of treatment is illustrated in the Kaplan-Meier curve presented in Figure 1. The RTX retention rates (95% Confidence Interval [CI]) at 1, 2, 3, 4, and 5 years) were 89.8% (85.0-94.8%), 77.2% (70.6-84.5%), 65.9% (58.3-74.5%), 57.1% (49.0-66.7%), and 54.9% (46.6-64.7%), respectively (Supplemental file).

The cumulative incidences of RTX discontinuation for specific reasons are depicted in Figure 2. Clinical response was the most common cause of RTX discontinuation occurring at the rate of 5.7 (3.7-8.4) per 100 patient-year and was associated with a shorter disease duration (sHR 0.8, 95% CI 0.7-0.9), anti-topoisomerase-I negativity (sHR 0.4, 95% CI 0.2-0.9), history of DUs (sHR 2.6, 95% CI 1.1-6.2), and absence of arthritis (sHR 0.3, 95% CI (0.1-0.8) (*Supplemental Figure 1*).

Both, at 6 months and at final follow-up, skin score was significantly improved in the entire cohort (mRSS: 11.9±8.0 and 8.3±7.4 vs *baseline*: 16.5±9.6) and in particular in dcSSc patients characterised by skin disease progression (mRSS: 15.6±9.6 and 9.2±7.9 vs 21.0±10.8) ( $p < 0.001$  for both comparisons). At 6 months and at final follow-up, mean predicted (%) FVC and DLCO remained stable in the entire cohort (FVC: 87.3±21.5 and 87.0±23.5 vs 87.4±19.8; DLCO: 65.2±20.9 and 61.1±19.6 vs 62.1±19.7) and in ILD patients (FVC: 84.7±19.2 and 82.5±21.6 vs 81.6±17.8; DLCO: 64.5±19.0 and 57.9±18.5 vs 60.6±18.7) ( $p = ns$  for all).

Considering only the 26 patients who discontinued RTX for clinical response, both at 6 months and at final follow-up, skin score was significantly improved (mRSS: 14.0±10.3 and 8.2±7.1 vs *baseline*: 19.7±9.3) ( $p < 0.001$  for both comparisons). Similarly, mean predicted (%) FVC and DLCO remained stable at 6 months and at final follow-up (FVC: 82.3±21.5 and 82.1±21.1 vs *baseline*: 86.3±19.9; DLCO: 63.6±20.8 and 62.3±21.5 vs *baseline*: 64.0±22.1) ( $p = ns$  for all).

1  
2  
3 Considering the 26 patients who discontinued RTX due to clinical response, the majority of them  
4 were already treated with DMARDs (92.3%) before RTX, and 13 of them (50%) were concomitantly  
5 treated with DMARDs.  
6  
7

8  
9  
10 Treatment failure was the second cause of RTX discontinuation occurring at 3.7 (95% CI 2.2-6.0) per  
11 100 patient-year, and was associated with anti-centromere antibody positivity (sHR 2.8, 95% CI 1.1-  
12 7.4) and anti-topoisomerase-I negativity (sHR 0.2, 95% CI 0.1-0.6) (*Supplemental Figure 2*). To date,  
13  
14 however, considering the 7 patients with anti-centromere positivity who discontinued RTX for  
15 treatment failure, all of them had a severe disease, refractory to previous DMARDs and that  
16 subsequently required anti-fibrotic and/or biologic therapy or AHSCT; moreover, in 4 of these cases  
17  
18 RTX was mainly started for refractory digital ulcers or calcinosis.  
19

20  
21  
22 Considering the 20 patients who discontinued RTX due to treatment failure, all of them were already  
23 treated with DMARDs before RTX, and 15 of them (75%) were concomitantly treated with  
24 DMARDs, mainly mycophenolate. After RTX discontinuation, at latest available follow-up (median  
25 39 [23.25 - 51.50]), 16 out of 20 (80%) of patients needed further therapies: tocilizumab was initiated  
26 in 6 patients (30%) and nintedanib in 4 (20%); 3 patients, moreover, underwent AHSTC, and 1 patient  
27 each received cyclophosphamide, intravenous immunoglobulins, or JAK-inhibitors.  
28

29  
30  
31 Overall, 42 AEs were recorded, mild infection being the most frequent (19.1%), followed by  
32 hypersensitivity reactions (15.1%) and mild leukopenia (15.1%). However, in only 14 cases AEs led  
33 to drug discontinuation (9.2%): 7 infusion reactions, 4 severe infections, 2 cardiovascular events  
34 (including one case of myocarditis after SARS-CoV-2 infection and one severe persistent  
35 hypotension) and one cytopenia (*Supplemental Table 2*). The occurrence of AEs was the less common  
36 cause of RTX discontinuation at a rate of 3.1 (95% CI 1.7-5.2) per 100 patient-year, associated with  
37 limited cutaneous subset (sHR 3.4, 95% CI 1.2-9.7) and previous MMF treatment (sHR 4.5, 95% CI  
38 1.2-16.3) (*Supplemental figure 3*). AEs occurred after a median time of 6 [1.0-24.0] months after  
39  
40 RTX initiation with high variability with some patients presented infusion reactions rapidly emerging  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 after first RTX cycle (18 AEs occurring in the first 3 months after RTX), and patients presented with  
4  
5 late occurring AEs (18 AEs occurring more than 6 months after RTX cycle).  
6

7  
8 Considering the 14 patients who discontinued RTX due to AEs, all of them were already treated with  
9  
10 DMARDs before RTX, and 12 of them (85.7%) were concomitantly treated with DMARDs, mainly  
11  
12 mycophenolate.  
13

14  
15 Changes in therapy after rituximab discontinuation due to clinical response, clinical failure and AEs  
16  
17 are reported in Supplemental File.  
18

19  
20 The retention rate was not associated with the clinical indication for RTX therapy, nor with the  
21  
22 autoantibody profile or the previous and concomitant therapies. Furthermore, the retention rate was  
23  
24 not associated with the therapeutic regimen at first RTX course and during follow-up, the use of RTX-  
25  
26 O versus RTX-B, or the decision to repeat RTX courses every 6 months or as clinically needed (p not  
27  
28 statistically significant for all the comparisons).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

Our long-term, real-life data suggest that RTX is a safe treatment in SSc patients, with limited impact from AEs on treatment retention. Indeed, AEs emerged as the least frequent cause of RTX discontinuation over a 5-years follow-up period. Overall, AEs leading to drug discontinuation were recorded only in 14 patients (9.2%), predominantly due to infusion reactions.

As about treatment efficacy, RTX was shown not only to be effective in the whole population, but its administration was able to counteract disease activity especially in SSc patients with early disease and a more favorable antibody profile. Indeed, one of the most striking results of our study was the observation that clinical response emerged as the primary reason for RTX discontinuation, associated with shorter disease duration and anti-topoisomerase I negativity. However, the association of RTX discontinuation for clinical response anti-topoisomerase-I negativity need to be taken with caution. The disease specific autoantibody profile in two third of patients with anti-topoisomerase and anti-centromere negativity who discontinued RTX for clinical response, indeed, was not clarified.

The hypothesis that RTX could be especially effective in early-stage of the disease has been previously suggested [5, 22-24]. The clinical usefulness of RTX on skin and lung involvement in patients with <3 years of disease duration, indeed, emerged in 2 studies assessing the role of B-cell depleting therapy in SSc [5,22]. In early SSc, an interplay between innate immunity, the pro-inflammatory/pro-fibrotic cytokine milieu and the adaptive immunity involving T-cells and B-cells dysregulation has been described [25,26]. In fact, B-cells infiltration in the skin is present in early diffuse cutaneous disease and correlates with fibrosis progression [27]. This evidence provides a biologic rationale for using RTX in the early stages of the disease to slow down progression to fibrosis. However, the efficacy of RTX must be rigorously investigated through randomized trials, because the B-cell depleting therapy may be an early intervention to modify disease progression by interfering with the immune-inflammatory process leading to fibrosis.

Recently, nintedanib has been shown to reduce the annual rate of decline of FVC in SSc ILD in a double-blind placebo-control study [3], leading to approval of its use for the treatment of ILD in SSc.

1  
2  
3 Unfortunately, this treatment did not demonstrate a significant effect on skin involvement in the  
4 SENSICIS trial [3]. Similarly, the primary end-point for skin improvement was not met in the  
5 FaSScinatate trial with tocilizumab [6], although it did show beneficial effects on lung function.  
6  
7  
8 Finally, no medications have shown definitive benefits for other disease manifestations, including  
9 musculoskeletal, cardiac, and gastro-intestinal involvement.

10  
11 Although our study was not specifically designed to assess the efficacy of RTX in specific disease  
12 manifestations of SSc, the RTX-related improvement of skin fibrosis and stabilization of lung  
13 function over long term use was confirmed. This aligns with findings from previous studies [4,5,22-  
14 24] and has been recently supported by the data from EUSTAR registry [9,28]. Comparable results  
15 have been also obtained with RTX biosimilars [11], and these findings are further backed by meta-  
16 analyses [10, 29,30] and the recent DESIRES trial [7]. However, even considering the DESIRES trial  
17 extension study [12], it only reported the efficacy and safety of RTX up to 48 weeks, leaving gap in  
18 long-term data. Our study, therefore, provides the longest follow-up available on RTX in SSc patients,  
19 offering insights on real-life, long-term efficacy and safety of the drug. Interestingly, considering  
20 patients who discontinued RTX for clinical response, after drug discontinuation the majority of them  
21 remained stable during a long follow-up even without any DMARDs as maintenance therapy, or by  
22 continuing the same DMARD as before RTX.

23  
24 The likelihood of discontinuing RTX due to clinical response was not influenced by the therapeutic  
25 regimen at the initial RTX course and during follow-up, nor by the decision to repeat RTX courses  
26 every 6 months or as clinically needed. Remarkably, 10% of our patients responded to one cycle,  
27 suggesting a specific disease phenotype or a window of opportunity where B-cell blockade is a critical  
28 intervention in the disease's progression.

29  
30 Considering the long period of observation of our study, however, we have to consider that our data  
31 mirror probably also the modification in use of RTX in SSc patients over recent years.

32  
33 Treatment failure was the second most common reason for discontinuing RTX, associated with anti-  
34 centromere antibody positivity and anti-topoisomerase-I negativity. This association is not surprising,  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 considering that skin and lung progression – the two primary indications for RTX - are more frequent  
4 in patients with anti-topoisomerase-I positivity [1,2], and studies on RTX efficacy in SSc have mainly  
5 reported a skin improvement and a lung function stabilization [4,5,22-24]. Therefore, we can  
6 hypothesize that anti-centromere positive patients might have a lower chance to respond to RTX  
7 therapy, because the clinical phenotype of these patients was different and more heterogenous. In  
8 fact, in our cohort, anti-centromere positivity was linked to disease manifestations where RTX  
9 efficacy is less established, such as DUs and calcinosis, and with clinical features suggesting a  
10 refractory disease. Interestingly though, the percentage of patients concomitantly treated with  
11 conventional DMARDs among those who discontinued RTX due to treatment failure was higher  
12 compared to those who discontinued RTX for clinical response (75% vs 50%), thus indirectly  
13 suggesting that patients who discontinued RTX due to treatment failure had a more severe disease.  
14 No safety concerns emerged in patients treated with a combined immunosuppressive regimen.

15  
16 Our study has some limitations: firstly, its retrospective nature inherently restricts the possibility to  
17 draw definitive conclusion, and, secondly, the clinical indications for initiating RTX and for repeated  
18 courses in patients not prescribed with a fixed retreatment scheme were largely based on physicians'  
19 judgment. However, the study was conducted in national SSc referral centres, ensuring high expertise  
20 in disease management and homogeneity in treatment decisions. However, the significant lack of  
21 data on anti-topoisomerase-I negativity and anti-centromere negativity did not allow to identify any  
22 association between autoantibody profile and the clinical response to RTX. Eventually, the data were  
23 collected over more than 13 years during which diagnostic approaches, monitoring strategies, and  
24 therapeutic management of SSc patients evolved, influencing the clinical indications for RTX therapy  
25 and for RTX re-treatment, as well as the definition of clinical response.

26  
27 In conclusion, our real-life long-term data indicate that RTX is a safe treatment for SSc patients with  
28 AEs having a limited impact on treatment persistence, allowing a long lasting treatment.  
29 Additionally, our data confirm the efficacy of RTX, which is seen especially in early SSc. In the next  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 future, the identification of specific disease features and autoantibody profile associated with a  
4  
5 response to RTX will be useful in the management of SSc patients.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Acknowledgments:** we acknowledge GILS (Gruppo Italiano Lotta alla Sclerodermia) for supporting  
4  
5 the study.  
6  
7  
8  
9

10 **Funding:** No specific funding was received from any bodies in the public, commercial or not-for-  
11  
12 profit sectors to carry out the work described in this article.  
13  
14

15  
16  
17 **Conflict of interest:** The authors declare that they have no competing interests.  
18  
19

20  
21 **Data availability statement:** the data that support the findings of this study are available on request  
22  
23 from the corresponding author (GLD).  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Denton CP, Khanna D. Systemic sclerosis. *Lancet*. 2017 Oct 7;390(10103):1685-1699. doi: 10.1016/S0140-6736(17)30933-9. Epub 2017 Apr 13. Review. PMID: 28413064.
2. Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. *J scleroderma relat disord* 2017; 2(3): 137 – 152 DOI: 10.5301/jsrd.5000249.
3. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al; SENSICIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. *N Engl J Med*. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. PMID: 31112379
4. Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. *Semin Arthritis Rheum*. 2017 Apr;46(5):625-631. doi: 10.1016/j.semarthrit.2016.10.003. Epub 2016 Oct 13. PMID: 27839742
5. Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. *Semin Arthritis Rheum*. 2015 Feb;44(4):428-36. doi: 10.1016/j.semarthrit.2014.09.002. Epub 2014 Sep 8. PMID: 25300701.
6. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. *Lancet*. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4.
7. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIREs): a double-blind, investigator-initiated,

- 1  
2  
3 randomised, placebo-controlled trial. *Lancet Rheumatol.* 2021 Jul;3(7):e489-e497. doi:  
4 10.1016/S2665-9913(21)00107-7.  
5  
6  
7  
8 8. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with  
9 systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies.  
10 *Rheumatology (Oxford).* 2012 Jun;51(6):1017-26. doi: 10.1093/rheumatology/ker269.  
11 Epub 2011 Sep 7. Review. PMID: 21900368.  
12  
13  
14  
15  
16  
17 9. Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al; for  
18 EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in  
19 contemporary practice: a prospective cohort study. *Ann Rheum Dis.* 2019 Jul;78(7):979-  
20 987. doi: 10.1136/annrheumdis-2018-214816. Epub 2019 Apr 9. PMID: 30967395.  
21  
22  
23  
24  
25  
26 10. Moradzadeh M, Aghaei M, Mehrbakhsh Z, Arab-Bafrani Z, Abdollahi N. Efficacy and  
27 safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic  
28 review and meta-analysis. *Clin Rheumatol.* 2021 Oct;40(10):3897-3918. doi:  
29 10.1007/s10067-021-05698-4.  
30  
31  
32  
33  
34  
35 11. Campochiaro C, De Luca G, Lazzaroni MG, Zanatta E, Bosello SL, De Santis M, et al.  
36 Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian  
37 multicentre study. *Rheumatology (Oxford).* 2020 Dec 1;59(12):3731-3736. doi:  
38 10.1093/rheumatology/keaa136.  
39  
40  
41  
42  
43  
44 12. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy  
45 of rituximab in systemic sclerosis (DESIREs): open-label extension of a double-blind,  
46 investigators-initiated, randomised, placebo-controlled trial. *Lancet Rheumatol.* 2022  
47 Aug;4(8):e546-e555. doi: 10.1016/S2665-9913(22)00131-X.  
48  
49  
50  
51  
52  
53 13. Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al; RECITAL  
54 Investigators. Rituximab versus intravenous cyclophosphamide in patients with connective  
55 tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind,  
56  
57  
58  
59  
60

- 1  
2  
3 double-dummy, randomised, controlled, phase 2b trial. *Lancet Respir Med*. 2023  
4 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9.  
5  
6  
7  
8 14. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013  
9 classification criteria for systemic sclerosis: an American college of  
10 rheumatology/European league against rheumatism collaborative initiative. *Ann Rheum*  
11 *Dis*. 2013 Nov;72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424.  
12  
13  
14  
15 15. Bruni C, Buch MH, Furst DE, De Luca G, Djokovic A, Dumitru RB, et al. Primary systemic  
16 sclerosis heart involvement: A systematic literature review and preliminary data-driven,  
17 consensus-based WSF/HFA definition. *J Scleroderma Relat Disord*. 2022 Feb;7(1):24-32.  
18 doi: 10.1177/23971983211053246.  
19  
20  
21  
22  
23 16. Maurer B, Graf N, Michel BA, Muller-Ladner U, Czirjak L, Denton CP, et al. Prediction of  
24 worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the  
25 EUSTAR database. *Ann Rheum Dis*. 2015;74(6):1124–1131. doi: 10.1136/annrheumdis-  
26 2014-205226.  
27  
28  
29  
30 17. Khanna D, Clements PJ, Volkman ER, Wilhalme H, Tseng CH, Furst DE, et al. Minimal  
31 Clinically Important Differences for the Modified Rodnan Skin Score: Results from the  
32 Scleroderma Lung Studies (SLS-I and SLS-II). *Arthritis Res Ther*. 2019 Jan 16;21(1):23.  
33 doi: 10.1186/s13075-019-1809-y.  
34  
35  
36  
37 18. Baron M, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton C, et al. An Interim  
38 Report of the Scleroderma Clinical Trials Consortium Working Groups. *J Scleroderma*  
39 *Relat Disord*. 2019 Feb;4(1):17-27. doi: 10.1177/2397198318783926.  
40  
41  
42  
43 19. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization  
44 of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. *J*  
45 *Scleroderma Relat Disord*. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.  
46  
47  
48  
49 20. Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, et al.  
50 Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 OMERACT CTD-ILD Working Group. *J Rheumatol*. 2015 Nov;42(11):2168-71. doi:  
4 10.3899/jrheum.141182. Epub 2015 Mar 1.  
5  
6  
7  
8 21. Mäkinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess  
9 remission in rheumatoid arthritis? *Ann Rheum Dis*. 2005 Oct;64(10):1410-3. Epub 2005  
10 Jun 7.  
11  
12  
13  
14 22. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, et  
15 al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and  
16 histopathological study. *Ann Rheum Dis*. 2010 Jan;69(1):193-7. doi:  
17 10.1136/ard.2008.095463.  
18  
19  
20  
21  
22  
23 23. Thiebaut M, Launay D, Rivière S, Mahévas T, Bellakhal S, Hachulla E, et al. Efficacy and  
24 safety of rituximab in systemic sclerosis: French retrospective study and literature review.  
25 *Autoimmun Rev*. 2018 Jun;17(6):582-587. doi: 10.1016/j.autrev.2017.12.010.  
26  
27  
28  
29  
30  
31 24. Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE,  
32 Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion  
33 therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. *Semin*  
34 *Arthritis Rheum*. 2017 Apr;46(5):625-631. doi: 10.1016/j.semarthrit.2016.10.003.  
35  
36  
37  
38  
39  
40 25. Bosello S, De Luca G, Toluoso B, Lama G, Angelucci C, Sica G, et al. B cells in systemic  
41 sclerosis: a possible target for therapy. *Autoimmun Rev*. 2011 Aug;10(10):624-30. doi:  
42 10.1016/j.autrev.2011.04.013.  
43  
44  
45  
46  
47 26. De Luca G, Tomelleri A, Dagna L, Matucci-Cerinic M. The target on B cells in Systemic  
48 Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease  
49 progression to fibrosis. *Clin Rheumatol*. 2021 Jul;40(7):2529-2533. doi: 10.1007/s10067-  
50 021-05733-4.  
51  
52  
53  
54  
55  
56 27. Bosello S, Angelucci C, Lama G, Alivernini S, Proietti G, Toluoso B, et al. Characterization  
57 of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression.  
58  
59  
60

1  
2  
3 Arthritis Res Ther. 2018;20(1):75. doi: 10.1186/s13075-018-1569-0. PMID: 29669578;  
4  
5 PMCID: PMC5907298.  
6

- 7  
8 28. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al; EUSTAR  
9  
10 Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis  
11  
12 from the European Scleroderma Trial and Research (EUSTAR) group. *Ann Rheum Dis*.  
13  
14 2015 Jun;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522.  
15  
16  
17 29. Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P. Rituximab in the  
18  
19 treatment of systemic sclerosis-related interstitial lung disease: a systematic review and  
20  
21 meta-analysis. *Rheumatology (Oxford)*. 2021 Feb 1;60(2):557-567. doi:  
22  
23 10.1093/rheumatology/keaa550.  
24  
25  
26 30. de Figueiredo Caldas MMV, de Azevedo KPM, de França Nunes AC, de Oliveira VH,  
27  
28 Pimenta IDSF, de Araújo IDT, Neto FAB, da Silveira Gonçalves de Oliveira AK, Piuvezam  
29  
30 G. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis.  
31  
32 *Adv Rheumatol*. 2021 Feb 27;61(1):15. doi: 10.1186/s42358-021-00170-y.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Demographic and clinical characteristics of SSc patients.**

	<b>N=152</b>
Age (years), mean $\pm$ SD	47.3 $\pm$ 12.3
Females, n (%)	121 (79.6)
Disease duration (months), mean $\pm$ SD	146.9 $\pm$ 79.2
Diffuse cutaneous disease, n (%)	118 (77.6)
Anti-topoisomerase I, n (%)	96 (63.2)
Anti-centromere, n (%)	25 (16.4)
Anti-RNA polymerase III, n (%)	18 (11.8)
Others SSc-associated Abs, n (%)	13 (8.6)
Rheumatoid factor, n (%)	20 (14.1)
ACPA, n (%)	11 (7.9)
Overlap with rheumatoid arthritis, n (%)	23 (15.1)
Overlap with other CTDs, n (%)	13 (8.6)
Interstitial lung disease, n (%)*	115 (75.7)
Gastrointestinal involvement, n (%)	96 (63.2)
History of digital ulcers, n (%)	91 (59.9)
Active digital ulcers, n (%)	69 (45.4)
Musculoskeletal involvement, n (%)	63 (41.4)
Myositis, n (%)	21 (13.8)
Calcinosis, n (%)	26 (17.1)
Pulmonary arterial hypertension on RHC, n (%)	21 (13.8)
Primary heart involvement, n (%)	18 (11.9)
Renal involvement, n (%)	2 (1.4)

\*ILD defined as at least 10% of interstitial lung abnormalities or FVC <79%. RHC: right heart catheterization.

Abbreviations: SSc = systemic sclerosis; SD = standard deviation; n = number; Abs = antibodies; ACPA = anti-citrullinated peptide antibodies; CTDs = connective tissue diseases; RHC = Right Heart Catheterization.

**Table 2. Previous and concomitant therapies in the cohort of SSc patients treated with rituximab.**

<b>Previous therapies</b>	<b>N=152</b>
Patients who underwent previous immunosuppressive therapy, n (%)	141 (92.8)
Mycophenolate mofetil, n (%)	68 (44.7)
Mycophenolate daily dose (mg), mean $\pm$ SD	1931.0 $\pm$ 499.5
Total months of MMF therapy, mean $\pm$ SD	45.9 $\pm$ 68.5
Cyclophosphamide (total), n (%)	45 (29.6)
Intravenously CYC (, n (%)	26 (17.1)
Cyclophosphamide cumulative dose (g), mean $\pm$ SD	11.0 $\pm$ 7.3
Azathioprine or methotrexate, n (%)	19 (12.5)
Other bDMARDs, n (%)	9 (5.9)
<b>Concomitant therapies at first RTX course</b>	
Corticosteroids, n (%)	113 (74.3)
Steroids daily dose (mg), mean $\pm$ SD	4.9 $\pm$ 4.8
Higher steroids (>7.5 mg/day prednisone), n (%)	15 (9.8)
Concomitant DMARDs, n (%)	117 (77.0)
Methotrexate, n (%)	55 (36.2)
Mycophenolate mofetil, n (%)	57 (37.5)
Hydroxychloroquine, n (%)	19 (12.5)



Other DMARDs, n (%)	5 (3.3)
Concomitant therapy with nintedanib, n (%)	11 (7.2)
Calcium channel blockers, n (%)	95 (62.5)
Acetylsalicylic acid, n (%)	74 (48.7)
Intravenous iloprost, n (%)	104 (68.4)
Proton pump inhibitors, n (%)	130 (85.5)
ERAs, n (%)	48 (31.6)
PDE5i, n (%)	18 (11.8)

*SD= standard deviation; n= number; MMF= mycophenolate mofetil; CYC= cyclophosphamide; DMARDs= disease modifying anti-rheumatic drugs; ERAs= endothelin receptor antagonists; PDE5i= phosphodiesterase 5 inhibitors.*


**Figure 1. Rituximab retention rate.** The RTX retention rates (95% Confidence Interval [CI]) at 1, 2, 3, 4, and 5 years) were 89.8% (85.0-94.8%), 77.2% (70.6-84.5%), 65.9% (58.3-74.5%), 57.1% (49.0-66.7%), and 54.9% (46.6-64.7%), respectively.

**Figure 2. Rituximab discontinuation event rates and 5-year cumulative incidence.**

Fifty-one discontinuation events: clinical response (26), treatment failure (17), infusion reaction (7), infections (4), cardiovascular events (2), cytopenia (1).

Event	Rate per 100 patient-year	5-year cumulative incidence (%)
<b>Any discontinuation</b>	11.2 (8.4-14.8)	45.1 (35.3-54.4)
<b>Discontinuation due to AEs</b>	3.1 (1.7-5.2)	11.4 (6.5-17.9)
<b>Discontinuation due to failure</b>	3.7 (2.2-6.0)	13.8 (8.3-20.6)
<b>Discontinuation due to AEs or failure</b>	9.7 (7.0-13.0)	25.2 (17.7-33.3)
<b>Discontinuation due to clinical stability</b>	5.7 (3.7-8.4)	19.9 (13.4-27.2)


*AEs= adverse events.*



The rituximab retention rates (95% Confidence Interval [CI]) at 1, 2, 3, 4, and 5 years) were 89.8% (85.0-94.8%), 77.2% (70.6-84.5%), 65.9% (58.3-74.5%), 57.1% (49.0-66.7%), and 54.9% (46.6-64.7%), respectively.

149x149mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Rituximab discontinuation event rates and 5-year cumulative incidence. Fifty-one discontinuation events: clinical response (26), treatment failure (17), infusion reaction (7), infections (4), cardiovascular events (2), cytopenia (1).

219x199mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60